Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/jfprhc-2015-101306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immediate postpartum contraceptive implant placement and breastfeeding success in postpartum people at risk for low milk supply: A randomized non-inferiority trial.
Contraception
December 2024
Department of Environmental Health Sciences, Columbia Mailman School of Public Health, New York, NY, United States.
Objectives: Our goal was to measure the impact of postpartum contraceptive implant insertion timing on breastfeeding success and duration in a population at high-risk for low milk supply.
Study Design: We conducted a three-armed randomized non-inferiority study of postpartum people who plan to breastfeed and have known risk factors for low milk supply. Participants were randomized to one of three groups for the timing of implant placement: within 30 minutes of placental delivery, 24-72 hours postpartum, or 6+ weeks postpartum.
Hemiplegic migraine associated with etonogestrel 68 mg implant insertion case report.
Contraception
December 2024
Department of Obstetrics, Gynecology and Women's Health, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, United States.
We present a case of suspected induced intractable headaches and paralysis after receiving an etonogestrel 68 mg implant. After extensive neurological evaluation, the etonogestrel implant was removed and neurological symptoms resolved. The case raises concerns about a potential rare risk of progestin-containing contraceptives in patients with migraines with aura warranting further investigation.
View Article and Find Full Text PDFTips and tricks for the management of contraceptive etonogestrel implant in clinical practice: an Expert Opinion.
Eur J Contracept Reprod Health Care
December 2024
Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Article Synopsis
- The global use of long-acting reversible contraceptives (LARCs) is rising because they more effectively prevent unintended pregnancies compared to short-acting methods, especially in teens.
- LARCs include options like intrauterine devices and subcutaneous implants, with specialized training required for their application.
- This Expert Opinion focuses on the etonogestrel (ENG)-releasing implant, offering updated guidance on insertion, removal, and managing unscheduled bleeding based on extensive clinical experience.
Risk of early etonogestrel and levonorgestrel implant discontinuation in adolescents and adults.
BMC Public Health
November 2024
Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, 1873 Rama IV Road, Patum Wan, Patum Wan, Bangkok, 10330, Thailand.
Article Synopsis
- Etonogestrel and levonorgestrel contraceptive implants are effective for 3 and 5 years, respectively, but early removal before due date can lead to unintended pregnancies, particularly among adolescents.
- A study conducted at King Chulalongkorn Memorial Hospital analyzed early implant discontinuation from 2014 to 2019, finding a 19.3% overall discontinuation rate with intolerance to side effects, like abnormal bleeding, being the main reason for removal.
- Results indicated that adolescents had a lower likelihood of early discontinuation than adults, with factors such as free implants, continuous use, postpartum status, and having children contributing to reduced discontinuation rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!